Entering text into the input field will update the search result below

Avalon GloboCare's CAR-T therapy completes early-stage study in B-cell malignancies

Jun. 29, 2020 1:44 PM ETAvalon GloboCare Corp. (ALBT) StockALBTBy: Vandana Singh, SA News Editor1 Comment
  • Avalon GloboCare (AVCO -6.4%) completes Phase I first-in-human clinical study of its lead Chimeric Antigen Receptor (CAR) T-cell therapy candidate, AVA-001.
  • Nine out of ten patients with relapsed/refractory B-cell acute lymphoblastic leukemia achieved complete remission (CR rate of 90%) within one month after the initiation of AVA-001 therapy.
  • AVA-001 was generally well tolerated with minimal toxicities and adverse side effects; no neurotoxicity was observed.
  • All patients who achieved CR successfully proceeded to allogeneic bone marrow transplant with curative intent.

Recommended For You

About ALBT Stock

SymbolLast Price% Chg
FFO (FWD)
PE
Div Rate (TTM)
Yield (TTM)
Market Cap
Volume
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ALBT--
Avalon GloboCare Corp.